Responses
Psoriatic arthritis
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.